All IndicationsNeurology & CNSApprovedPhase 3Phase 3Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2
🧠
Alzheimer Disease
6
Companies
10
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
BIIB
Biogen Inc.
Leqembi
BreakthroughFast Track
SAVA
Cassava Sciences, Inc.
Simufilam
SNY
Sanofi
xaliproden (SR57746A)
BIIB
Biogen Inc.
BIIB080
BreakthroughFast TrackOrphan Drug
SNY
Sanofi
AVE1625
NRSN
NeuroSense Therapeutics Ltd.
PrimeC
ALEC
Alector Inc.
AL002
SAVA
Cassava Sciences, Inc.
Simufilam 100 mg oral tablet
SAVA
Cassava Sciences, Inc.
Placebo oral tablet
ALNY
Alnylam Pharmaceuticals, Inc.
ALN-APP
BreakthroughFast TrackOrphan Drug
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| BIIB Biogen Inc. | Leqembi | Approved | BTFT | — | — |
| SAVA Cassava Sciences, Inc. | Simufilam | Phase 3 | — | — | — |
| SNY Sanofi | xaliproden (SR57746A) | Phase 3 | — | — | — |
| BIIB Biogen Inc. | BIIB080 | Phase 2 | BTFTOD | — | — |
| SNY Sanofi | AVE1625 | Phase 2 | — | — | — |
| NRSN NeuroSense Therapeutics Ltd. | PrimeC | Phase 2 | — | — | — |
| ALEC Alector Inc. | AL002 | Phase 2 | — | — | — |
| SAVA Cassava Sciences, Inc. | Simufilam 100 mg oral tablet | Phase 2 | — | — | — |
| SAVA Cassava Sciences, Inc. | Placebo oral tablet | Phase 2 | — | — | — |
| ALNY Alnylam Pharmaceuticals, Inc. | ALN-APP | Phase 2 | BTFTOD | — | — |
Development Stage Distribution
Approved
1
Phase 3
2
Phase 2
7
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.